癌症患者对比增强CT检查所致急性肾损伤:白皮书强调其临床相关性并讨论适用的预防策略
该白皮书由意大利医学放射学学会年会专家讨论形成,旨在为癌症患者对比增强CT后急性肾损伤(PC-AKI)提供实用预防指南。文中指出碘对比剂所致AKI占所有AKI的11%,在全部CT检查中报告率高达2%,老年人、慢性肾病或糖尿病患者、脱水或使用肾毒性化疗药者风险增加。
要点
- 碘对比剂所致AKI占所有AKI的11%,在全部CT检查中报告率高达2%。
- 老年人、慢性肾病或糖尿病、脱水或使用肾毒性化疗药者发生PC-AKI风险增加。
- 白皮书以陈述形式描述降低癌症患者对比增强CT相关肾损伤风险的方法。
核心结论
- 癌症患者常需接受对比剂增强影像检查,应知晓降低对比剂后急性肾损伤风险的策略。
研究设计与样本
- 白皮书基于2018年意大利医学放射学学会年会四位放射学、肿瘤学和肾脏病学专家的讨论形成。
诊断标准与关键数值
- 碘对比剂所致AKI占所有AKI的11%,在全部CT检查中报告率高达2%。
临床应用与阅片要点
- 原发性护理医师及所有参与癌症患者管理的专科医师应知晓降低对比剂后急性肾损伤风险的策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Patients with cancer are subjected to several imaging examinations which frequently require the administration of contrast medium (CM). However, it has been estimated that acute kidney injury (AKI) due to the injection of iodinated CM accounts for 11% of all cases of AKI, and it is reported in up to 2% of all CT examinations. Remarkably, the risks of developing AKI are increased in the elderly, in patients with chronic kidney disease or diabetes, and with dehydration or administration of nephrotoxic chemotherapeutics. Given the common occurrence of postcontrast acute kidney injury (PC-AKI) in clinical practice, primary care physicians and all specialists involved in managing patients with cancer should be aware of the strategies to reduce the risk of this event. In 2018, a panel of four experts from the specialties of radiology, oncology and nephrology were speakers at the annual meeting of the Italian Society of Medical Radiology (Società Italiana di Radiologia Medica e Interventistica), with the aim of commenting on existing evidence and providing their experience on the incidence and management of PC-AKI in patients with cancer. The discussion represented the basis for this white paper, which is intended to be a practical guide organised by statements describing methods to reduce renal injury risks related to CM-enhanced CT examinations in patients with cancer.
引用
- Cosmai L, Porta C, Privitera C, et al. Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. ESMO Open. 2020. PMID: 32205339. doi:10.1136/esmoopen-2019-000618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。